United States Hereditary Angioedema Therapeutics Market Demand, Size and Competitive Analysis | TechSci Research

United States Hereditary Angioedema Therapeutics Market was valued at USD 846.80 million in 2023 and is anticipated to grow with a CAGR of 7.12% through 2029. <table><tr><td>Pages</td><td>82</td></tr> <tr><td>Market Size</td><td>2023: USD 846.80 million</td></tr> <tr><td>Forecast Market Size</td><td>2029: 1267.15 million</td></tr> <tr><td>CAGR</td><td>2024-2029: 7.12%</td></tr> <tr><td>Fastest Growing Segment</td><td> Prophylaxis</td></tr> <tr><td>Largest Market</td><td>Mid-West</td></tr> <tr><td>Key Players</td><td>1.BioCryst Pharmaceuticals, Inc.2.Ionis Pharmaceuticals, Inc.3.Seqirus Pty Ltd. (CSL Limited)4.Attune Pharmaceuticals, Inc.5.Adverum Biotechnologies, Inc.6.KalVista Pharmaceuticals, Inc.7.Takeda Pharmaceutical Company Limited8.Pharming Healthcare N.V.9.Sanofi AG10.Cipla Ltd.</td></tr> </table>

美国遗传性血管性水肿治疗市场在2023年估值达到8.468亿美元，预计在2024年至2029年期间以7.12%的复合年增长率持续增长。详见表格：

<table>
<tr>
<td>页数</td>
<td>82</td>
</tr>
<tr>
<td>市场规模</td>
<td>2023年：8.468亿美元</td>
</tr>
<tr>
<td>预测市场规模</td>
<td>2029年：12.6715亿美元</td>
</tr>
<tr>
<td>复合年增长率</td>
<td>2024-2029年：7.12%</td>
</tr>
<tr>
<td>增长最快的细分市场</td>
<td>预防性治疗</td>
</tr>
<tr>
<td>最大市场</td>
<td>中西部地区</td>
</tr>
<tr>
<td>主要参与者</td>
<td>1. BioCryst Pharmaceuticals, Inc. 2. Ionis Pharmaceuticals, Inc. 3. Seqirus Pty Ltd. (CSL Limited) 4. Attune Pharmaceuticals, Inc. 5. Adverum Biotechnologies, Inc. 6. KalVista Pharmaceuticals, Inc. 7. Takeda Pharmaceutical Company Limited 8. Pharming Healthcare N.V. 9. Sanofi AG 10. Cipla Ltd.</td>
</tr>
</table>